Core Viewpoint - The company is acquiring 100% equity of two subsidiaries, Shijian Qihua and Huada Xifeng, for a total price of 365.7 million yuan, aiming to integrate cutting-edge technologies in spatial genomics and nanopore sequencing [1] Group 1: Acquisition Details - The acquisition involves cash payments of 158 million yuan for Shijian Qihua and 207.7 million yuan for Huada Xifeng, with additional investments of 70 million yuan and 60 million yuan respectively to support their business development [2] - The company will also provide a loan of 7 million yuan to Huada Xifeng at an interest rate of 2.5% for three years to assist with repayments and daily operations [2] Group 2: Financial Projections - Both Shijian Qihua and Huada Xifeng are currently unprofitable, but are expected to achieve profitability by 2026 and 2028 respectively, with cumulative profit targets of at least 5.01 million yuan and 8.28 million yuan [3] - If the profit commitments are not met, Huada Technology will provide cash compensation, and any impairment beyond the cumulative compensation will also be compensated [3] Group 3: Strategic Integration - The integration of Shijian Qihua and Huada Xifeng is expected to enhance the company's technological ecosystem, creating a complete technical matrix for sequencing products [3] - The companies share a strong alignment in upstream suppliers and downstream customer bases, which is anticipated to facilitate rapid integration and collaboration post-acquisition [4] Group 4: Revenue Forecast - The company forecasts revenues of 2.918 billion yuan, 3.383 billion yuan, and 3.972 billion yuan for 2025-2027, with year-on-year growth rates of -3.15%, 15.94%, and 17.43% respectively [4] - The projected net profit for the same period is -233 million yuan, -11 million yuan, and 102 million yuan, with significant year-on-year growth rates of 61.20%, 95.42%, and 1052.54% [4]

Core Viewpoint - The company BGI Genomics (华大智造) announced a cash acquisition of 100% equity in Shenzhen Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xifeng Technology Co., Ltd., focusing on advanced technologies in spatial omics and nanopore sequencing [1][2] Group 1: Acquisition Details - The total transaction price for the acquisition is set at 36,570 million yuan, with Sanjian Qifa valued at 15,800 million yuan and BGI Xifeng at 20,770 million yuan [1] - Following the acquisition, the company plans to inject additional capital of 7,000 million yuan into Sanjian Qifa and 6,000 million yuan into BGI Xifeng [1] Group 2: Strategic Implications - The acquisition will provide the company with control over two cutting-edge technology platforms, enhancing its competitive edge and profitability in the long term [1] - Sanjian Qifa and BGI Xifeng are expected to achieve profitability by 2026 and 2028, respectively, marking a significant step in the company's strategic layout [2] - This move is aimed at improving the company's technological ecosystem and boosting its independent innovation capabilities in the gene sequencing field [2]